Dan Pollyea, MD, MS | Authors

Dan Pollyea, MD, MS, on Venetoclax and IDH Mutations in Patients With AML

January 21, 2021

The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.

Dan Pollyea, MD, MS, on the Discovery and Incidence of IDH1 and IDH2 mutations in Patients With AML

January 14, 2021

IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.

Daniel A. Pollyea, MD, on the Impact of Venetoclax in IDH-Mutant AML

December 30, 2020

The leukemia expert discussed the clinical implications of findings demonstrating improved response for patients with acute myeloid leukemia with IDH mutations.

Dan Pollyea, MD, on the Impact of Venetoclax in Patients With AML With IDH Mutations

December 24, 2020

Dan Pollyea, MD discusses the response rate and overall survival of venetoclax for patients with acute myeloid leukemia with IDH mutations.

Dan Pollyea, MD, Discusses Venetoclax For Patients With AML Harboring IDH Mutations

December 17, 2020

Pollyea discussed the rationale behind a study of venetoclax and azacitidine for patients with acute myeloid leukemia with IDH mutations